171 related articles for article (PubMed ID: 35551629)
1. A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human.
Montanha MC; Howarth A; Mohamed DA; Loier E; Main L; Rösslein M; Delmaar C; Prina-Mello A; Siccardi M
Drug Deliv Transl Res; 2022 Sep; 12(9):2178-2186. PubMed ID: 35551629
[TBL] [Abstract][Full Text] [Related]
2. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data.
Poirier A; Cascais AC; Funk C; Lavé T
Chem Biodivers; 2009 Nov; 6(11):1975-87. PubMed ID: 19937834
[TBL] [Abstract][Full Text] [Related]
4. Development of a multi-route physiologically based pharmacokinetic (PBPK) model for nanomaterials: a comparison between a traditional versus a new route-specific approach using gold nanoparticles in rats.
Chou WC; Cheng YH; Riviere JE; Monteiro-Riviere NA; Kreyling WG; Lin Z
Part Fibre Toxicol; 2022 Jul; 19(1):47. PubMed ID: 35804418
[TBL] [Abstract][Full Text] [Related]
5. Allometric scaling of pegylated liposomal anticancer drugs.
Caron WP; Clewell H; Dedrick R; Ramanathan RK; Davis WL; Yu N; Tonda M; Schellens JH; Beijnen JH; Zamboni WC
J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):653-69. PubMed ID: 21863380
[TBL] [Abstract][Full Text] [Related]
6. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
[TBL] [Abstract][Full Text] [Related]
7. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
Poulin P; Theil FP
J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
[TBL] [Abstract][Full Text] [Related]
8. Toward a general physiologically-based pharmacokinetic model for intravenously injected nanoparticles.
Carlander U; Li D; Jolliet O; Emond C; Johanson G
Int J Nanomedicine; 2016; 11():625-40. PubMed ID: 26929620
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
10. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
Peters SA
Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
[TBL] [Abstract][Full Text] [Related]
12. Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling.
Lee JB; Zhou S; Chiang M; Zang X; Kim TH; Kagan L
Biopharm Drug Dispos; 2020 Apr; 41(4-5):192-205. PubMed ID: 32342986
[TBL] [Abstract][Full Text] [Related]
13. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
14. A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release.
Nagpal S; Braner S; Modh H; Tan AXX; Mast MP; Chichakly K; Albrecht V; Wacker MG
Eur J Pharm Biopharm; 2020 Aug; 153():257-272. PubMed ID: 32589926
[TBL] [Abstract][Full Text] [Related]
15. An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice.
Chou WC; Chen Q; Yuan L; Cheng YH; He C; Monteiro-Riviere NA; Riviere JE; Lin Z
J Control Release; 2023 Sep; 361():53-63. PubMed ID: 37499908
[TBL] [Abstract][Full Text] [Related]
16. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
17. Endocytosis mechanism in physiologically-based pharmacokinetic modeling of nanoparticles.
Deng L; Liu H; Ma Y; Miao Y; Fu X; Deng Q
Toxicol Appl Pharmacol; 2019 Dec; 384():114765. PubMed ID: 31669777
[TBL] [Abstract][Full Text] [Related]
18. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.
Luo R; Li Y; He M; Zhang H; Yuan H; Johnson M; Palmisano M; Zhou S; Sun D
Int J Pharm; 2017 Mar; 519(1-2):1-10. PubMed ID: 28063903
[TBL] [Abstract][Full Text] [Related]
19. A physiologically-based pharmacokinetic model for predicting doxorubicin disposition in multiple tissue levels and quantitative toxicity assessment.
Chao FC; Manaia EB; Ponchel G; Hsieh CM
Biomed Pharmacother; 2023 Dec; 168():115636. PubMed ID: 37826938
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
